Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Melvin Sharoky, M.D., a director of INSMED Inc (INSM), reported multiple transactions on Form 4 reflecting gifts and a market sale. The filing shows gift transactions (Code G) and a sale of 10,000 shares on 09/12/2025 at a weighted average price of $145.39 per share. Following the reported sale and other transactions, the reporting person directly beneficially owns 262,675 shares. The report also discloses indirect holdings through entities Baby Gator LLC and Padonia, LLC and multiple custodial UTMA accounts where the reporting person is custodian.
Insmed, Inc. (INSM) reporting person S. Nicole Schaeffer, Chief People Strategy Officer and director, reported a non-derivative disposition on 09/04/2025. The filing shows a gift (Transaction Code G) of 23,303 common shares at a price of $0, leaving 56,461 shares beneficially owned directly after the transaction. No derivative transactions were reported. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Insmed, Inc. (INSM) Chief Legal Officer Michael A. Smith reported transactions on 09/02/2025. Mr. Smith exercised stock options to acquire 12,780 shares at an exercise price of $30.46 and immediately sold multiple blocks of common stock under a Rule 10b5-1 trading plan. The sales totaled 24,252 shares at weighted average prices ranging from $140.58 to $146.04 per share, reducing his reported beneficial ownership from 79,174 shares to 54,902 shares. All exercised options are currently exercisable and the transactions were effected pursuant to a 10b5-1 plan adopted February 27, 2025.
Martina Flammer, M.D., Chief Medical Officer of Insmed Inc. (INSM), reported multiple option exercises and subsequent open-market sales on 09/02/2025 under a 10b5-1 trading plan. The filing shows the exercise of stock options at strike prices ranging from $17.07 to $34.03, converting options into shares (total option exercises listed include 186,943 underlying shares across multiple option grants). Following exercises, the report lists a series of sales on the same date totaling 209,066 shares sold at weighted-average prices between $140.56 and $146.51, with incremental remaining beneficial ownership reported at 83,111 shares after the transactions. The Form 4 notes the 10b5-1 plan was adopted on February 27, 2025, and includes vesting schedules for each option series.
JPMorgan Chase & Co. filed an amendment to Schedule 13G reporting beneficial ownership of 23,014,584 shares of Insmed Incorporated common stock (CUSIP 457669307), representing 10.8% of the class. The filing breaks down voting and dispositive powers: 20,997,990 shares with sole voting power and 22,971,006 shares with sole dispositive power; smaller amounts are held with shared powers. The filing lists affiliated entities through which holdings are held, including J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank NA, and various asset management and international affiliates. The filing certifies the shares are held in the ordinary course of business and not for the purpose of influencing control.
Form 144 filed for Insmed, Inc. (INSM) reporting a proposed sale of common stock. The notice lists a proposed sale of 186,648 shares through Merrill Lynch (Washington, DC) with an aggregate market value of $26,935,498 and total shares outstanding of 211,374,786. The shares to be sold were acquired on 09/02/2025 under a stock plan and the payment/settlement date is the same day. The filing also discloses that the reporting person, Martina Flammer, sold 55,564 shares during the past three months for aggregate gross proceeds of $5,190,291 across four transactions dated 06/03/2025 to 08/04/2025. The form includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insmed, Inc. reported a Form 144 notice for the proposed sale of 24,272 common shares through Merrill Lynch on Nasdaq, with an aggregate market value of $3,491,647.00 and an approximate sale date of 09/02/2025. The filing lists multiple stock-plan acquisitions by the seller throughout 2024–2025 totaling 31,272 shares acquired (individual grants dated 07/08/2024, 01/04/2025, 01/06/2025, 01/07/2025, 02/05/2025 and 09/02/2025). It also discloses sales by the same person during the past three months: 933, 748, 1,879 and 1,448 shares generating stated gross proceeds of $95,617; $72,114; $138,050; and $103,532 respectively. The filer certifies no undisclosed material adverse information and follows the Rule 144 notice requirements.
Insmed, Inc. (INSM) Form 4 shows Director Melvin Sharoky reported a sale of 10,000 shares of Insmed common stock on 08/20/2025 at a reported price of $129.50 per share. After the sale, the reporting person beneficially owns 274,516 shares, held directly and indirectly through various entities and UTMA custodial accounts.
The filing lists multiple indirect holdings: 100 shares held for Owen F. Paley UTMA/FL, 900 by Baby Gator LLC, 10,000 by Padonia, LLC, and additional amounts held for family members and custodial accounts. The report was signed by Melvin Sharoky via attorney-in-fact on 08/21/2025.
Insmed Inc. insider sale disclosure: The company's Chief Operating Officer, Roger Adsett, reported selling a total of 25,000 shares of Insmed common stock on 08/19/2025 in two transactions. The filings show 20,193 shares sold at a weighted-average price of $127.42 (range $127.00–$127.99) and 4,807 shares sold at a weighted-average price of $128.27 (range $128.00–$128.72). After these sales, the report lists beneficial ownership of 110,444 shares in one line and 105,637 shares in another line, each reported as direct ownership. The Form 4 was signed via power of attorney.
Insmed Inc. insider transactions by Chair and CEO William Lewis show option exercises and multiple stock sales executed under a 10b5-1 plan on 08/18/2025. The filing reports the exercise of 6,865 stock options at an exercise price of $10.85 and the acquisition of 6,865 common shares via that exercise. On the same date the reporting person sold a total of 6,865 common shares in separate sell transactions: 2,968 shares at a weighted average price of $127.59, 2,481 shares at $128.76, and 1,416 shares at $129.47. After these transactions the reporting person beneficially owns 303,911 shares indirectly and 50,500 shares indirectly via two trusts.